Loading stock data…
CRISPR Therapeutics AG (CRSP)
$57.72-1.65 (-2.78%)
Market ClosedLast close Aug 28
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
CRISPR Therapeutics AG in the Healthcare sector is trading at $57.72 with a market capitalization of $5.6B. Wall Street consensus targets $87.56 (18 analysts), implying a +51.7% move over the next 12 months. The stock is currently 26% below its 52-week high of $78.48, remaining 8.6% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +51.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $10.00M↑ | $1.00M | $0 | $0 | $0 |
| Gross Profit | -$30.27M↑ | -$44.95M↑ | -$53.70M↑ | -$57.12M↓ | -$45.15M |
| Operating Income | -$117.27M↑ | -$130.25M↑ | -$154.76M↓ | -$132.06M↑ | -$229.32M |
| Net Income | -$91.15M↑ | -$122.93M↑ | -$130.61M↓ | -$106.44M↑ | -$208.55M |
Peer Comparison
JNJUNHPFE
Fundamentals
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The compan...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.58B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.74
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-25.83%
Volume
Today's trading volume
1.39M
Recent News
Vertex Pharmaceuticals Up 15% in a Month: How to Play the Stock
Vertex's stock is up 15% in a month as strong CF sales, rising non-CF drug revenues and renal pipeline progress boost its growth story.
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains
CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and promising early-stage programs.
CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money?
This year, the biotech stock has underperformed both the Nasdaq Biotechnology Index and the S&P 500.
Crispr Therapeutics Posts "Quiet" Quarter as Casgevy Advances, SiRNA Data Readouts Near, RBC Says
Crispr Therapeutics (CRSP) reported a relatively quiet Q2, with Casgevy continuing to gain commercia
VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised
Vertex's Q2 earnings miss estimates, but revenues beat. It lifts its 2026 sales outlook, and sees growing contributions from newer products.